痰热清注射液治疗成人重症肺炎疗效及安全性分析

Efficacy and Safety of Tanreqing Injection on Treating Adults Severe Pneumonia

目的：研究分析痰热清注射液治疗成人重症肺炎的治疗效果及安全性。方法：在Cochrane Library、Medline、Embase、OVID、VIP和CNKI-中国期刊全文数据库（1980—2015年）中检索2015-08-01之前对国内外公开发表的有关于痰热清注射液治疗成人重症肺炎的临床疗效随机对照临床试验文献（randomized clinical trial,RCT）。采用Jadad质量评分标准进行评价,对纳入的文献采用Review Manager 5.3软件进行Meta分析。结果：共纳入10篇随机对照试验,共762例患者符合纳入标准,纳入本Meta分析。Meta分析结果显示：经齐性检验,纳入7篇研究具有同质性（χ2=3.49,P=0.75,I2=0）,采用固定效应模式,结果显示痰热清注射液组治疗成人重症肺炎的治愈率优于对照组,综合优势比（OR）为0.49,95%可信区间为（0.31,0.76）,整体效益检验Z=3.14,P〈0.002;纳入10篇研究具有同质性（χ2=7.16,P=0.62,I2=0）,采用固定效应模式,结果显示痰热清注射液组治疗成人重症肺炎的总有效率优于对照组,综合优势比（OR）为0.31,95%可信区间为（0.21,0.47）,整体效益检验Z=5.56,P〈0.00001。结论：经有限的证据显示,痰热清注射液治疗成人重症肺炎具有良好的治疗效果及安全性,在临床治疗中具有重要作用。因本次研究缺乏高质量的随机对照研究,因此应用痰热清注射液治疗成人重症肺炎具有良好的治疗效果及安全性还需要更多的高质量临床研究来予以进一步证实。

Objective： We want to analyze the treatment effect and safety of Tanreqing Injection on treating adults＇ severe pneumonia. Methods ： We searched before 2015-08-01 Coehrane Library, Medline, Embase, OVID, VIP and CNKI- Chinese Academic Journal （ 1980--2015 ）was published at home and abroad about Tanreqing treatment of adults severe pneumonia abuh clinical efficacy of randomized controlled clinical trials literature （ randomized clinical trial, RCT ） . Jadad quality score using the evaluation criteria for inclusion of literature using Review Manager 5.3 software Mate analysis. Results ： A total of 10 randomized controlled trials, a total of 762 cases of patients met the inclusion criteria, included in this Meta analysis. Meta-analysis showed： The homogeneity test included seven studies homogeneity （ X 2=3-49, P=0.75, I^2=0 ）, using the fixed effects model, the results show Tanreqing group treatment of adults with severe pneumonia, the cure rate than the control group, the comprehensive advantages of ratio （OH）was 0.49,95% CI （0.31,0.76）, the overall effectiveness of inspection and Z=3.14, P〈0.002; 10 studies included homogeneity （ X 2=7-16, P=0.62, I^2=0 ）, using the fixed effects model, the results show Tanreqing treatment of adults with severe pneumonia group total efficiency than the control group, the comprehensive advantages of the ratio （OR）was 0.31,95% CI （0.21,0.47）, the overall effectiveness of inspeetion and Z=5.56, P〈0.00001. Conclusion： The limited evidence suggests Tanreqing treatment of adults with severe pneumonia have a good therapeutic effect and safety plays an important role in the clinical treatment. Because high-quality RCTs lack this study, so the application Tanreqing treatment of adults with severe pneumonia have a good therapeutic effect and safety needs more high-quality clinical studies to be further confirmed.